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The most commonly employed screening method for proteinuria is a semi- 
quantitative dipstick urinalysis, but it has been shown to be inaccurate in pregnancy. 
New developments in the assessment of proteinuria have included the use of urinary 
albumin measurements. The Clinitek  Microalbumin Reagent Strip (Bayer 
Healthcare LLC, USA) is a semi-quantitative dipstick test. It is used to measure the 
spot urinary microalbumin to creatinine ratio that is read using the Clinitek 50 
portable urine chemistry analyzer. 
 
Aims 
We embarked on a pilot study to validate the Clinitek 50 system by determining the 
accuracy of spot urinary microalbumin to creatinine ratio dipsticks and conventional 
visual dipsticks (Makromed ) compared to the laboratory urinary microalbumin to 
creatinine ratio quantification to detect significant proteinuria in normotensive and 
hypertensive antenatal attendees. The accuracy of spot urinary microalbumin to 
creatinine ratio dipsticks and conventional visual dipsticks were then compared to a 
24 hour urinary protein (gold standard) to detect significant proteinuria in 
hypertensive disorders of pregnancy. We then determined the role of proteinuria as 
assessed by the diagnostic accuracy of both the 24 hour urinary protein (gold 
standard) and the spot urinary microalbumin to creatinine ratio dipstick, in pregnancy 
outcomes of these participants. 
 
Methods 
This was a prospective study conducted at hospitals serving the Durban Metropolitan 
region in South Africa. To validate the urinary microalbumin to creatinine ratio 




hypertension in pregnancy were recruited .Each women had a spot midstream urine, 
which was assessed for proteinuria using a semi-quantitative visual dipstick 
(Makromed ) and analysed using the semi-quantitative urinary microalbumin to 
creatinine ratio dipsticks (Clinitek® Microalbumin) read on the Clinitek® 50 urine 
chemistry analyser. A result of 1 + on visual dipsticks and a spot urinary 
microalbumin to creatinine ratio UAC of > 300mg/g (33.9mg/mmol) was considered 
as positive for significant proteinuria. The results were compared to the laboratory 
quantitative measurement of the urinary microalbumin to creatinine ratio. 
 
The study group comprised 163 women presenting with newly diagnosed 
hypertension during pregnancy after 20 weeks of gestation, being recruited from 
antenatal clinics. Each participant had a spot urine sample that was tested by trained 
midwives for proteinuria using a semi-quantitative visual dipstick (Makromed ). 
Participants were admitted to the ward where a spot midstream urine sample was 
collected and analysed using the semi-quantitative urinary microalbumin to creatinine 
ratio dipsticks. A 24 hour quantitative urinary protein analysis was completed. The 
results of the urinary microalbumin to creatinine ratio dipsticks and conventional 
visual dipsticks were compared to the 24 hour urinary protein (gold standard) to detect 
significant proteinuria. A urinary microalbumin to creatinine ratio of < 300mg/g (nil 
and trace on visual urine dipsticks) was considered to be a negative result. A urinary 
microalbumin to creatinine ratio  300 mg/g (1+ to 4+ on visual urine dipsticks) was 
considered to be a positive result. Urinary protein   0.3 g/24 hours was considered 
significant proteinuria. The outcomes of pregnancy in 2 sub-categories viz. those with 
and without significant proteinuria were compared using the 24 hr urinary protein 
measurement. A secondary analysis of outcomes of pregnancy was performed by 
subcategorizing the participants according to the diagnostic accuracy of the urinary 









In the 26  patients enrolled in the  initial study , the visual dipstick had a sensitivity of 
25% ( 95% CI [0.04-0.64] ) and specificity  of  89% ( 95% CI [0.64 -0.98]).The 
urinary microalbumin to creatinine ratio dipsticks had  a sensitivity of  88% ( 95% CI  
[0.47-0.99]), specificity of 89% (95% CI [0.64-0.98]), negative predictive value      
(NPV) of 94% (95% CI [0.69-1.00]) and positive predictive value (PPV) of 78% 
(95% CI [0.40-0.96]). 
In the 163 patients subsequently enrolled the visual dipstick had a sensitivity of 51 % 
( 95% CI [0.41-0.61]) and specificity of 91% (95% CI [0.81-0.96]) .The PPV and 
NPV was 89 %( 95% CI [0.77-0.95]) and 58% (95% CI [0.48-0.67]) respectively. The 
urinary microalbumin to creatinine ratio dipsticks had a sensitivity of 63% (95% CI 
[0.52-0.72]) and specificity of 81 % (95% CI [0.70-0.89]). The PPV was 82% (95% 
CI [0.71-0.90]) and NPV was 62% (95% CI [0.51-0.71]).  
 
Our results show that in hypertensive pregnant women, significant proteinuria 
determined by the quantitative 24 hour urinary protein is associated with delivery at 
an earlier gestational age, increased induction of labour and lower birthweights 
compared to the non-proteinuric hypertensives (gestational hypertension). There is 
also a trend towards an increased maternal morbidity and perinatal mortality. When 
the groups were classified into pre-eclampsia and gestational hypertension using the 
diagnostic accuracy of the urinary microalbumin to creatinine ratio dipsticks, there 
were no differences in the clinical outcomes between the false negatives and true 
negatives except a trend towards a higher caesarean section rate in the false negatives. 
 
Conclusion 
The urinary microalbumin to creatinine ratio dipstick read on the Clinitek 50 system 
provides a semi – quantitative result of the urinary microalbumin to creatinine ratio 
that has good sensitivity and specificity. Furthermore, the urinary microalbumin to 
creatinine ratio dipstick has a good negative predictive value and a result of                






Both the visual dipstick (Makromed ) and the urinary microalbumin to creatinine 
ratio dipstick read on the Clinitek 50 system are not accurate when compared to the 
total 24 hour urinary protein. Differences between the urinary microalbumin to 
creatinine ratio and 24 hour total  urinary protein may be due to the variation in the 
albumin fraction of the total urinary  protein of pre-eclampsia, technical problems 
with imprecision of the  assay technique and clinical causes of false positives and 
negatives. The improved sensitivity of the automated urinary microalbumin to  
creatinine ratio dipstick over the visual dipstick suggests it may be a suitable 
substitute for the visual dipstick in clinical practice  
 
Hypertension in pregnancy associated with significant proteinuria is associated with 
greater adverse maternal and fetal outcome. Outcome of pregnancy is similar when a 
classification of gestational hypertension is made based either on the 24 hour urinary 
protein or the urinary microalbumin to creatinine ratio dipstick read on the Clinitek 50 
system. The urinary microalbumin to creatinine ratio dipstick is a good screening test 
to rule out significant proteinuria. It has the potential to improve accuracy of 
screening for proteinuria and enhancing safety by preventing incorrect diagnosis and 
unnecessary investigation. Further research is required to determine its full impact and 















Hypertensive disorders of pregnancy are a major cause of maternal and perinatal 
mortality worldwide. In well resourced countries such as the UK, hypertensive 
disorders of pregnancy (HDP) were second only to thromboembolism as the main 
cause of maternal death (Lewis, 2004). In the United States, HDP represented almost 
15% of pregnancy related deaths (Report of the National High Blood Pressure 
Education Program Working Group on High Blood Pressure in Pregnancy, 2000). In 
South Africa, it has been the commonest cause of direct primary obstetric related 
deaths since 1998, and accounted for 19.1% of maternal deaths in the triennial report 
2002-2004 (Saving Mothers, 2006).The Confidential Enquiry into Stillbirths and 
Deaths in Infancy report in the UK cited one in six stillbirths as occurring in 
pregnancies complicated by maternal hypertension (Maternal and Child Health 
Research Consortium, 1998). Long term healthcare implications for women who 
develop HDP include an increased risk of developing cardiovascular complications 
later in life (Haukkamaa et al., 2004; Ramsay et al., 2003; Wilson et al., 2003) and 
their offspring have an increased risk of hypertension, heart disease and diabetes 
(Smith and Kenny, 2006).    
 
 POSSIBLE AETIOLOGY 
 
Of the HDP, pre-eclampsia remains the leading cause of maternal and perinatal 
mortality (Smith et al., 2006).While the aetiology of pre-eclampsia remains unknown, 
there has been extensive research trying to elucidate the key steps in this multisystem 
disease process. Pre-ecalmpsia is primarily thought to be caused by a maternal 
response to abnormal placentation while other theories have included ischaemia 
leading to oxidative stress within the placenta and maternal circulation, and immune 










Key steps proposed in the disease process include deficient remodelling of the spiral 
arterioles in early pregnancy leading to placental ischaemia and an increase in 
placental oxidative stress that results in the release of circulating factors that target 
maternal vascular endothelium and this in turn causes maternal and fetal effects 
(Smith et al., 2006).   
 
 SCREENING  
 
Many screening tests for predicting pre-eclampsia based on dysfunction of placental 
perfusion, vascular resistance, endocrinology and the fetoplacental units have been 
described. A systematic review conducted by the World Health Organization ( WHO)   
to evaluate these screening  methods found the majority of them to have low 
predictive potential and thus not suitable for use in routine clinical practice ( Conde-
Agudelo et al., 2004). Antenatal screening therefore consists predominantly of 
detection of a raised blood pressure and proteinuria. Once detected, treatment of pre-
eclampsia has remained delivery of the fetus and placenta for the last century.  
 
 BLOOD PRESSURE MEASUREMENTS 
 
Advancements in blood pressure measurement have involved the development of 
automated blood pressure measuring equipment. Unlike the mercury 
sphygmomanometer that relies on detecting Korotkoff sounds, these devices evaluate 
oscillometric signals obtained from a cuff during deflation. They have an advantage of 
removing observer error and facilitating repeated measurements and patient self 
monitoring. However, a number of studies have demonstrated that oscillometric 
measurement is inaccurate in hypertensive pregnancies (Villar et al., 2004). 
Individual machines may produce large errors and it is recommended that each device 
be validated for accuracy using protocols published by the Advancement of Medical 











 MEASUREMENT OF PROTEINURIA 
 
There have been several advancements in the detection of proteinuria since the 
nineteenth century.  It was in 1827 that Bright boiled a teaspoon of urine and 
discovered “albuminous urine” in patients with oedema and related this to severe and 
protracted disease of the kidneys (Bright et al., 1827). In 1843, the obstetrician John 
Lever separated the proteinuria of pregnant women in whom hypertension was 
developing from that of “Morbus Brightii” (Bright‟s disease). Since this discovery, 
proteinuria has been used to define pre-eclampsia and classify disease severity. 
Patterns of proteinuria have also been investigated to distinguish pre-eclampsia from 
other proteinuric diseases (Karumanchi et al., 2007).  
 
Traditionally a quantitative 24 hour total urinary protein excretion has been used to 
quantify proteinuria. New developments in proteinuria assessment have included the 
use of urinary albumin measurements. While small amounts of albumin can be 
detected in the urine of a healthy population, the term microalbuminuria (MA) has 
been used to refer to a range of urinary albumin excretion that is above the reference 
ranges but below amounts referred to as significant proteinuria. In the non pregnant 
population MA has been extensively studied. It has been used as a marker to predict 
an increase risk of cardiovascular and renal disease in the general population, in type 
1 and 2 diabetics and in patients with essential hypertension (Hillege et al., 2002; 
Gerstein et al., 2001). 
 
In the pregnant population, there is limited literature regarding MA.  It has been used 
as a clinical tool to predict pre-eclampsia and as an early predictor of hypertensive 
complications and perinatal outcome (Das et al., 1996; Bar et al., 1996; Nakamura et 
al., 1992; Chhabra et al., 2002).Waugh et al., (2005a) have suggested that MA may 
correlate better with other clinical measurements of disease severity as it may more 
accurately reflect the glomerular dysfunction associated with the glomerular 










 Microalbuminuria dipsticks compared to the traditional visual urinary dipsticks have 
also been shown to be a better screening test for clinically significant proteinuria 
(Higby et al., 1995; Waugh et al., 2005a). Various semi quantitative dipstick tests 
have been used for detection of MA. The Clinitek Microalbumin Reagent Strip (Bayer 
Corporation, Elkhart, IN) is an example of semi- quantitative dipstick test for MA that 
is read using the Clintek 50 portable urine chemistry analyzer (Figure 1). This type of 
automated point of care urine analyzers are able to provide rapid results, avoiding 
inter observer error and provide automated documentation of results. However, unlike 
automated blood pressure measuring devices, no established protocols exist for 







































































Hypertensive disorders of pregnancy include chronic hypertension, gestational 
hypertension, pre-eclampsia and chronic hypertension with superimposed pre-
eclampsia (Table 1) (Davey et al., 1988). Pre-eclampsia is a multisystem disorder of 
unknown aetiology that is unique to human pregnancy. The International Society for 
the study of Hypertension in pregnancy (ISSHP) defines pre-eclampsia as the 
occurrence of hypertension in combination with proteinuria developing after 20 weeks 
gestation in a previously normotensive, non-proteinuric patient (Davey et al., 1988). 
Hypertension is defined as a blood pressure of at least 140mmHg (systolic) or at least 
90 mmHg (diastolic) on two occasions 4- 6 hours apart. Proteinuria is defined as the 
excretion of 300mg or more of protein every 24 hours. If 24 hour urine samples are 
not available, proteinuria is defined as a protein concentration of 300mg /l or more 
(≥1 + on dipstick) in at least two random urine samples taken at least 4-6 hours apart 
or a spot protein to creatinine ratio of 30 mg/mmol or more (Sibai et al., 2005). In 
order to detect pre-eclampsia, blood pressure measurement and dipstick analysis of 

















































1.6 RISK FACTORS  
 
Classification of Hypertensive disorders of pregnancy 
 
Pre-eclampsia / Eclampsia 
Gestational Hypertension 
Chronic Hypertension 







A systematic review of controlled trials by Duckitt et al., (2005) found the unadjusted 
relative risks (RR) for developing pre-eclampsia were antiphospholipid antibodies  
( RR 9.72 , 95% confidence interval (CI) [4.34-21.75]), history of pre-eclampsia (RR 
7.19, 95% CI [5.85-8.83] ),  pre-existing diabetes (RR 3.56, 95% CI [2.54-4.99] ), 
multiple pregnancy (RR 2.93, 95% CI [2.04-4.21] ), nulliparity (RR 2.91, 95% CI 
[1.28-6.61] ), family history of pre-eclampsia (RR 2.90, 95% CI [1.70-4.93] ), 
nulliparous women aged  40 (RR 1.68, 95% CI [1.23-2.29] ), multiparous women 
aged  40 (RR 1.96, 95% CI [1.34-2.87] ), and a raised body mass index (BMI)  at 
booking (RR 1.55, 95% CI [1.28-1.88] ) (Table 2).The risk of pre-eclampsia is also 
increased  with pre-existing hypertension and renal disease, a preganacy interval of    
 10 years and a raised diastolic blood pressure at booking, and confirmed proteinuria   
( Duckitt et al.,2005 ; Milne et al.,2005).These evidence based risk factors have been 
recommended for use by the NICE guidelines (2003) and the pre-eclampsia 
community guideline (PRECOG) (Milne F et al., 2005) to screen for likelihood of  the 











































1.7 PATHOPHYSIOLOGY OF PRE-ECLAMPSIA 
 
1.7.1 ‘DISEASE OF THEORIES’ 
Risk factors for Pre-eclampsia 
 
 RR 95%CI 
antiphospholipid antibodies 9.72   4.34-21.75 
history of pre-eclampsia 7.19 5.85-8.83 
pre-existing diabetes 3.56 2.54-4.99 
multiple pregnancy 2.93 2.04-4.21 
nulliparity 2.91 1.28-6.61 
family history of pre-eclampsia 2.90 1.70-4.93 
nulliparous women aged  40 1.68 1.23-2.29 
multiparous women aged  40 1.96 1.34-2.87 








Pre-eclampsia has often been claimed to be the „disease of theories‟. While the exact 
aetiology of pre-eclampsia is unknown, there is substantial evidence that the placenta, 
in particular the trophoblast is necessary for the development of this disorder (Shah et 
al., 2007; Redman et al., 2000 and 2005; Roberts et al., 2000 and 2001). The spectrum 
of the clinical syndrome varies and is thought to be due to maternal endothelial 
dysfunction.  
 
The endothelial dysfunction is thought to arise from placental hypoxia with oxidative 
stress or from the interaction between a normal placenta and conditions that make the 
mother susceptible to microvascular disease like chronic hypertension, diabetes 
mellitus and renal disease (Redman et al., 2005). Often it is due to a combination of 
the above, resulting in the wide spectrum of disease presentation.  
 
There are currently two main theories regarding the primary precipitating factor in the 
disease process. In the two stage model it is suggested that a relative reduction in 
placental blood flow secondary to either defective placentation or maternal 
microvascular disease leads to release of circulating factors that cause endothelial 
dysfunction and that this gives rise to the clinical features seen (Roberts et al.,2002; 
Smith et al.,2006) (Figure 2).  
 
In the continuum theory it is suggested that pre-eclampsia is predisposed to by factors 
that increase the maternal systemic inflammatory response to pregnancy. It is 
suggested that this is in response to a relative increase in trophoblastic debris that may 
be caused by a large placenta, an abnormal stimulus from a small placenta, or an 



































































1.7.2 ‘UTEROPLACENTAL’ MODELLING IN NORMAL PREGNANCY 
 
In pregnancy the spiral arteries undergo various physiological changes to be 
transformed into „uteroplacental‟ vessels. Trophoblastic invasion occurs in two phases 
with the first occurring between 6 to 12 weeks of gestation and the second between 14 
























This invasion of maternal tissue at the implantation site consists of vascular and 
interstitial invasion (Shah, 2007). Zhou et al., (1997) found that cytotrophoblast cells 
transform from an epithelial phenotype to an endothelial phenotype as they invade the 
myometrium. Integrins (receptors that bind extracellular matrix ligands including 
fibronectin, lamnin and collagen), cadherins (molecules that mediate cell to cell 
adhesion) and immunoglobulin superfamily adhesion receptors (VCAM-1 AND 
PECAM-1) play an important role in invasion and acquisition of an endothelial 
phenotype (Zhou et al., 1997; Roberts et al., 2002). 
 
 This transformation is brought about by upregulating the expression of adhesion 
molecules such as vascular endothelial-cadherin (VE-cadherin) and V 3  integrin and 
downregulation of molecules that restrain invasion (α6 4, E-cadherin) and is thought 
to be required for successful endovascular invasion and normal placentation. These 
changes secondary to trophoblastic invasion transform the spiral arterioles into a high 
flow; low pressure system in order to support the pregnancy. Interstitial invasion 
consists of cytotrophoblasts invading the decidual tissue between blood vessels by 










1.7.3 ‘UTEROPLACENTAL’ MODELLING IN PRE-ECLAMPSIA 
 
Impaired placentation in pre-eclampsia has been attributed to failure of trophoblasts to 
adopt an endothelial phenotype and endovascular invasion failing to proceed beyond 
the superficial portions of the spiral arteries in early pregnancy (Zhou et al., 1997; 








Disordered expression of several adhesion molecules that are normally involved in the 
conversion to an endothelial phenotype are thought to be responsible for the shallow 
implantation with limited vascular invasion (Zhou et al., 1997).Pijnenborg et al., 
(1996) found impaired trophoblast attachment on fibronectin and vitronectin in pre-
eclamptic pregnancies, which may reflect differences in expression of matrix 
receptors.  
 
Immunological factors have also been thought to contribute to defective trophoblastic 
invasion. Interaction between the Natural Killer (NK) cells and trophoblasts are 
important in placentation and may be defective in pre-eclampsia. Extravillous 
trophoblasts express a combination of human lymphocyte antigens (HLA) class 1 
molecules, namely HLA-C, HLA-E and HLA-G, which are all ligands for NK cell 
receptors. From these, HLA-C is the only polymorphic antigen that signals paternal 
antigens ( Redman et al., 2005; Parham et al.,2005).Killer immunoglobulin like 
receptors (KIRs), are NK receptors that recognize polymorphisms of HLA-C. 
Pregnant women who are homozygous for group A KIR haplotypes and carry a fetus 
that expresses HLA-C2 are at highest risk of pre-eclampsia ( Redman et al., 2005; 
Parham et al.,2005). Group A KIRs haplotypes inhibit NK cells and it is thought that 
in pre-eclampsia overly inhibited NK cells may lead to understimulation of 
trophoblasts (Parham et al., 2005). 
 
In pre-eclampsia spiral arteries that would normally achieve a mean diameter of 500 
microns have reduced distensibility and only achieve a mean diameter of 200 microns 
(Shah, 2007). This altered vascular modelling results in reduced placental perfusion  
 
 
and relative ischaemia occurs.  
 
1.7.4 ENDOTHELIAL DYSFUNCTION IN PRE-ECLAMPSIA 
 
Maternal endothelial dysfunction is responsible for the clinical features of the disease. 
Hypertension results from enhanced vascular sensitivity to angiotensin II and 
norepinephrine with subsequent vasoconstriction. This is further aggravated by a 







oxide. Increase endothelial cell permeability results in leakage of protein from the 
intravascular space giving rise to oedema and proteinuria. Platelet aggregation results 
due to an imbalance of aggregatory and anti-aggregatory factors. These include 
prostacyclin, thromboxane and serotonin (Sibai et al., 2005). 
 
According to the two stage model, the hypoxic placenta releases factors into the 
maternal circulation that results in an exaggerated systemic inflammatory response of 
which endothelial dysfunction is a key component. Recently there has been much 
interest in factors that are thought to be responsible. Vascular endothelial growth 
factor (VEGF) is an angiogenic factor that is expressed by the placenta (Shah, 2007). 
It plays an important role in blood pressure regulation and in maintaining the integrity 
of the glomerular filtration barrier (Maynard et al., 2003). 
 
Soluble film- like tyrosine kinase (sflt), also known as soluble vascular endothelial 
growth factor receptor (sVEGFR) is elevated in pre-eclampsia and is associated with 
decreased free VEGF and placental growth factor ( PlGF) (Maynard et al.,2003; 
Shibata et al.,2005; Mutter et al.,2007). Over expression of sflt1 in rats leads to 
hypertension, proteinuria and  glomerular endotheliosis , which are characteristic of 
the clinical manifestations of pre-eclampsia suggesting that this factor may have a 
causal role in pre-eclampsia (Maynard et al.,2003). However, sflt1 is not raised in 
every women affected, suggesting that other factors may play a role.Endoglin (Eng), a 
placental derived soluble transforming growth factor  co-receptor, an anti – 
angiogenic factor, is elevated in patients with pre-eclampsia (Venkatesha et al.,2006).  
 
 
Administration of sflt1 together with Eng in pregnant rats results in a pre-eclampsia 
like syndrome including features of HELLP ( haemolysis, elevated liver enzymes, low 
platelets) syndrome suggesting that these two factors may work in concert 
(Venkatesha et al.,2006).  
 
 
1.8 RENAL CHANGES IN NORMAL PREGNANCY 
 








The kidney is composed of many glomeruli. Each glomerulus serves as a filtering unit 
that allows the passage of water and small molecules while serving as a barrier to 
larger molecules like albumin. The glomerular filtration barrier is composed of three 
layers which include an endothelial layer, the glomerular basement membrane and the 
epithelial cell layer composed of cells called podocytes. 
 
The glomerular filtration rate (GFR) refers to the ultrafiltrate of plasma across the 
above mentioned layers (Hladunewich, 2005). Glomerular filtration rate depends upon 
effective renal plasma flow (ERPF), the ultrafiltration coefficient „Kf‟ (the product of 
the available surface area for ultrafiltration and the porosity of that surface) and 
Starling forces acting across the glomerular wall (the net oncotic pressure and the 
transglomerular hydrostatic pressure difference) (Moran et al., 1999). 
 
Passage of solutes through the glomeruli is determined by their size and charge 
selectivity. The podocyte layer that lines the Bowman‟s capsule is thought to be the 








1.8.2 PROTEINURIA AND GLOMERULAR FILTRATION RATE IN   
NORMAL PREGNANCY 
 
The methods of screening for proteinuria and the level of significant proteinuria in 
HDP have remained controversial. In the non-pregnant women daily urine protein 
excretion averages 20-80 mg/day with an upper limit of protein excretion of two  
standard deviations above the mean or 150 mg /day. This consists of 40% albumin, 
15-20 % immunoglobulin (IgG 5-10%, IgA 3% and light chains 5-10 %) and the 
remainder is Tamm-Horsfall glycoprotein derived from the tubules and the lower 








In normal pregnancy, GFR and ERPF increase by approximately 50%. Clinically,  
GFR is determined by measuring creatinine clearance (CC). Creatinine clearance 
reliably correlates with GFR provided that a complete urine collection is obtained 
during an accurately timed period. Creatinine clearance is significantly increased by 4 
weeks gestation, peaks at 9-11 weeks gestation and is then sustained until the 36th 
week of gestation. In the last four weeks of pregnancy CC reduces by 15-20 % 
(Davison et al., 1980). In pregnancy CC may be increased to values of 150-
200ml/min. These renal haemodynamic changes result in greater quantities of colloids 
and solute passing by the glomerular barrier per unit time. 
 
 In addition there are changes in glomerular permeability and altered tubular 
reabsorption of filtered proteins that may result in increased excretion of protein. Thus 
it is normal in pregnant women for total protein excretion (TPE) and urinary albumin 
excretion (UAE) to be significantly elevated after the 20th week of gestation 
(Maybury and Waugh, 2004).Currently the accepted upper limits of normal for 
protein excretion in pregnancy are 300mg/24 hours for TPE and 30mg/24 hours for 
UAE (Higby et al.,1994). Kuo et al (1992) have suggested that a threshold for 
pregnancy should be lowered to 200mg /24 hours for TPE but it is the 300mg 




1.9 RENAL CHANGES IN PRE-ECLAMPSIA 
 
 In pre-eclampsia there is a reduction of both GFR and ERPF by 30-40%  
compared with normal pregnancy (Lafayette et al., 1998; Moran et al., 2003).It is 
postulated that the basis for the hypofiltration is largely secondary to structural 
changes in the glomerulus as opposed to renal vasoconstriction with a depression in 
renal plasma flow (Hladunewich, 2005). Rarely, prolonged renal hypoperfusion with  
resulting acute tubular necrosis can occur in severe pre-eclampsia.  
 
Proteinuria may rarely precede hypertension but usually accompanies or follows it. 







but occasionally persists for months. Pre-eclampsia is the leading cause of nephrotic 
syndrome during pregnancy. Protein excretion may vary from less than a gram to 8 to 
10 g per day. The urinary sediment is usually bland with red blood cells and cellular 
casts being rare (Karumanchi et al., 2005). 
 
In pre-eclampsia, glomeruli undergo structural changes with endothelial vacuolization 
and hypertrophy of the cytoplasmic organelles defined as glomerular endotheliosis 
(Spargo et al., 1959). Loss of both size and charge selectivity of the glomerular barrier 
contribute to the development of albuminuria (Moran et al., 2003).The proteinuria of 
pre-eclampsia is thus considered to be non-selective. Figure 4 provides a schematic 
representation of the glomerular filtration barrier with the characteristic changes 
accompanying pre-eclampsia.  
 
Recently, Garovic et al., (2007) demonstrated the presence of 4 podocyte markers 
(podocin, podocalyxin, synaptopodin, and nephrin) in patients with pre-eclampsia at 
the time of delivery. Podocyturia (i.e., urinary excretion of podocytes) may contribute 
to proteinuria in pre-eclamptics and may indicate loss of podocytes from the 









Figure 4: Schematic representation of the glomerular filtration barrier with 
























1.10 PROTEINURIA AND PREGNANCY OUTCOME 
There are several key questions that need to be answered when one looks at the 
relationship between proteinuria and pregnancy outcome. These include:  
1. How has the threshold for significant proteinuria been determined and does it have 
any correlation to clinical outcome? 
2. Is proteinuric hypertension associated with greater adverse maternal and fetal 
outcome? 
3.   Is the severity of adverse maternal and fetal outcomes related to the degree of      
      proteinuria? 
 
1. How has the threshold for significant proteinuria been determined and does it 
















Proteinuria above a threshold of ≥ 300mg/24 hours has been used as a criterion to 
differentiate pre-eclampsia from gestational hypertension in the classification system 
for hypertensive disorders of pregnancy (Davey and MacGillivray, 1998).It is used 
both as a marker of severity and disease progression. The threshold for significant 





) to define significance. Higby et al., (1994) published the 
first adequate study establishing normal urinary protein and albumin excretion in 
pregnancy. They reported figures of 260mg per 24 hour for urinary protein and 29 mg 
per 24 hour for albumin as the upper limit of normal excretion during pregnancy and 
also found that there was a statistically significant increase in protein excretion after 
20 weeks of gestation. Waugh et al., (2005a) in a prospective study of 197 women 
found that whilst 300mg/24 hours may be above the 95
th
 centile for an obstetric 








2. Is proteinuric hypertension associated with greater adverse maternal and fetal 
outcome? 
 
Proteinuria associated with hypertension in pregnancy is associated with greater 
adverse maternal and fetal outcome. In pregnant women with mild chronic 
hypertension but no proteinuria, the outcome of pregnancy is similar to non - 
hypertensive pregnant women (Sibai et al., 1983) whilst hypertension together with 
proteinuria is associated with poor fetal outcome, an increased rate for small for 
gestational age pregnancies, increased perinatal mortality and maternal morbidity      
(Chan et al., 2005; Brown et al., 1996; Ferranzani et al., 1990; Chua and Redman, 








3. Is the severity of adverse maternal and fetal outcomes related to the degree of 
proteinuria? 
 
There is conflicting evidence in the literature regarding the degree of proteinuria and 
adverse maternal and fetal outcome. Chan et al., (2005) found that in women with pre-
eclampsia, the probability of adverse maternal outcomes increased with both 
increasing maternal age and increasing spot urine protein to creatinine ratios. They 
found that a spot protein to creatinine ratio of 900mg/mmol or more for all ages, was 
associated with an increase in risk of developing adverse maternal outcomes 
(likelihood ratio for a positive result of 7 or more).The probability of adverse fetal 
outcome was also increased with an increasing spot urine protein to creatinine ratio 
and was significantly greater when gestation at initial presentation was less than 34 
weeks. Chan et al., (2005) however could not determine a specific spot protein to 
creatinine ratio that could be used as a definitive screening test for adverse outcomes. 
Other studies have suggested that the severity of proteinuria is not proportionally 
linked to increasing adverse maternal and fetal outcomes. Chua et al., (1992) found 
that delivery was necessary within 2 weeks of the onset of heavy proteinuria (> 5g/24 
hours) in 88.1% of cases and that in a subset of more preterm pregnancies, 
pregnancies could be safely prolonged for up to 4 weeks with intensive monitoring. 
 
 
Schiff et al., (1996) concluded in a retrospective study that the amount of proteinuria 
and the rate of increase in proteinuria during conservative management were not 
important predictors of maternal and perinatal outcome. A prospective study by Hall 
et al., (2001) similarly found that significant increases in proteinuria or heavy 
proteinuria was not associated with poorer maternal and fetal outcomes compared to 
smaller increases of proteinuria of < 5g/24 hours. Newman et al., (2003) found in a 
retrospective review that the magnitude of proteinuria, even when massive (> 10g/24 
hours), did not correlate with increased maternal or neonatal morbidity in pre-
ecampsia. They concluded that neonatal morbidity appeared to be more a function of 
prematurity rather than massive proteinuria itself. 
 
 








Proteinuria is assessed most appropriately by the biochemical quantitative 
measurement of total protein excretion over a 24-hour period. This is an impractical 
screening test. The most commonly employed screening method for proteinuria 
antenatally is a semi-quantitative dipstick urinalysis (Halligan et al., 1999). 
 
Several studies have questioned the value of dipstick urinalysis. Kuo et al., (1992) 
compared the dipstick diagnosis of significant proteinuria in 24-hour urine collections 
with dipstick urinalysis in 68 hypertensive pregnant women admitted to hospital with 
0.3g/l proteinuria on urinalysis. They found a wide range of total protein values at a 
urine score of 1+ on dipstick urinalysis.  
 
Meyer et al., (1994) retrospectively reviewed case records of 300 hypertensive 
women. They reported that 60 % of women with a negative or trace dipstick result 
had significant proteinuria defined as  0.3 g protein/24 hours and a significant false 





Brown et al., (1995) compared ward urinalysis for protein obtained on a midstream 
sample before and after a 24-hour urine collection and compared this with the 24-hour 
urine protein excretion. Urinalysis was also performed on a mixed aliquot of each 24-
hour urine sample. The positive predictive value for urinalysis ranged from 38 % (pre- 
collection) to 60% (for test on 24 hour aliquot). Negative predictive values ranged 
from 86 to 88% respectively.  
 
Waugh et al., (2001) found that the amount of protein assessed quantitatively was 
dependent on the biochemical assay employed. The positive and negative predictive 
values for urine dipstick analysis were dependent on the type of assay used as the gold 
standard. They however found that dipstick urinalysis has a significant false negative 








Gangaram et al., (2005) evaluated the accuracy of dipstick urinalysis in a single 
voided urine sample and in an aliquot of a 24-hour urine collection in the assessment 
of proteinuria in 198 hypertensive pregnant women, using the 24-hour urine protein 
excretion as the gold standard. The positive predictive value (PPV) for dipstick 
urinalysis ranged from 64.9% (single voided urine sample) to 94.2% (24 hour urine 
aliquot). The negative predictive value (NPV) ranged from 75.2% (single voided urine 
sample) to 84.2% (24 hour urine aliquot). 
 
These studies show that random semi-quantitative dipstick analysis in the diagnosis of 
proteinuria in pregnancy is imprecise and its value is questionable. False positive 
results may subject patients to the inconvenience of over investigation and 
unnecessary interventions, while false negative results may jeopardise the health of 








1.12 INACCURACY OF DIPSTICK URINALYSIS- THE ROLE OF  
         AUTOMATION 
 
There are several factors that may contribute to the inaccuracy of urine dipstick 
analysis. These include observer error (Bell et al., 1999) and factors that may 
influence concentration of protein in an individual urine specimen such as 
contamination, exercise, posture, osmolality and urinary pH (Halligan et al., 1999). 
 
 In order to overcome inter observer errors, automated technology has been introduced 
to read the urine dipstick. Saudan et al., (1997) found that an automated urinalysis 
device (Clinitek 100 Ames) improved the positive predictive value of urinalysis from 
24% to 47% at the 1+ (0.3 g/l) concentration and from 53% to 83% at the 2+ (1g/l) 
concentration, without significantly altering the false negative rate. Although the 







persistently high rates of false positives encountered at the 1+ level, though only to 
half the extent of the visual urinalysis. 
 
Waugh et al., (2005b) performed a study comparing visual dipstick testing with 
automated methods. They found automated dipstick testing has a significantly better 
positive (PPV 78% vs. 64%) and negative predictive value (NPV 84% vs. 65%) for 
















1.13 LABOROTARY MEASUREMENT OF PROTEINURIA – THE ‘GOLD   
           STANDARD’ 
 
 
There is a lack of a clear „gold standard‟ for quantitative measurement of proteinuria. 
There are currently more then ten different assays, none of which has gained universal 
acceptance. This makes it difficult to compare the outcomes of various studies with 
similar methodology where there are differences in the assay used as the laboratory 
gold standard. 
 
 In pregnancy, Waugh et al., (2001) compared urine dipstick analysis to the 
Benzethonium chloride assay and the Bradford assay. They found a variation between 
dipstick urinalysis and the two different assays and attributed this to protein assay 
specificity and the observed protein compositions of the samples on electrophoretic 
analysis. Thus the measurement of proteinuria is dependent on the type of assay used 









1.14 PROTEIN:CREATININE RATIOS IN SPOT URINE SAMPLES 
 
The gold standard for determining protein excretion is the 24 hour urine collection.  
The need for a 24 hour collection is due to the variation in protein excretion during 
the day. Factors that may contribute to this variation include variation in water intake 
and excretion, rate of diuresis, exercise, recumbency and diet (Price et al., 2005).  
 
The major problem with the 24 hour protein collection is that it is often impractical in 
the outpatient setting with problems of incomplete collection. In order to overcome 
this, the spot protein to creatinine ratio has been proposed. During the day urinary 
protein and creatinine excretion rates are fairly constant provided the glomerular 
filtration rate is constant. Thus a ratio of the concentrations of urinary protein and 
creatinine in a single voided urine sample would reflect the cumulative excretion 
during the day since the ratio of two stable rates would cancel out the time factor 
(Ginsberg et al., 1983).   
 
 
Recent studies have suggested a strong correlation between the protein/ creatinine 
ratio and 24 hour urine protein level in women with pre-eclampsia. Jaschevatzky et 
al., (1990) measured the protein:creatinine ratio in 35 pre-eclamptic patients and 70 
healthy pregnant women. They found a close correlation between the protein/ 
creatinine ratio in random urine samples and the 24 hour protein excretion (r =0.927; 
p <0.001) and the 24-hour protein:creatinine ratio (r =0.920; p <0.001) in the pre-
eclamptic patients. 
 
 Besides showing a significant correlation between the 24 hour urine protein and the 
protein:creatinine ratio (r = 0.93; p < 0.001), Neithardt et al., (2002) in addition found 
that the protein:creatinine ratio appears to predict trends in protein excretion over 
time.  
 
Other studies have found contradictory results. Durnwald et al., (2003) found a poor 
correlation (r² =0.41) between the protein:creatinine ratio in 220 women with 







p < 0.01) in patients with new onset mild hypertension in late pregnancy. A 
systematic review by Price et al., (2005) concluded that there was sufficient data to 
demonstrate a strong correlation between the protein:creatinine ratio in a random 
urine sample and 24 hour protein excretion. They also found that protein:creatinine 
ratio in a random urine sample might be used to rule out significant proteinuria as 
defined by a 24 hour urine excretion measurement. 
To increase the applicability of the use of the protein:creatinine ratio in clinical 
practice semi-quantitative protein:creatinine ratio dipsticks have been developed.  Roy 
et al., (2003) described the first assessment of a protein:creatinine ratio dipstick 
(Autistics Pro: Bayer Diagnostics).They tested a midstream urine of 171 hypertensive 
pregnant women with protein:creatinine ratio dipsticks on a validated Urinanalyser 
(Clinitek 50: Bayer diagnostics) and compared this with the use of visual and 
automated dipstick analysis using the 24 hour total protein measurement as the gold  
 
 
standard. They found the sensitivity (94.5%) and specificity (95.7%) of the 
protein:creatinine ratio dipsticks to be superior to visual dipstick urinalysis for the 
prediction of 300mg protein / 24 hours at the 1+ threshold. 
 
1.15 MICROALBUMINURIA 
1.15.1 HISTORY OF MICROALBUMINURA 
The term microalbuminuria (MA) was first used by Viberti et al., (1981) to describe 
urinary excretion rates of albumin that could not be detected by standard urinary 
dipsticks, but only by more sensitive assays for albumin, to predict development of 
overt proteinuria in diabetic patients. While the clinical utility of MA has been largely 
studied and applied in diabetic populations to screen and monitor for incipient 
nephropathy, more recently it has been found to be an independent predictor of 
cardiovascular disease in patients with diabetes, hypertension and in the general 







Ruggenenti et al., 2006). It has also been suggested as a marker of endothelial 
dysfunction (Verdecchia et al., 2004). These findings have led to an increased interest 
in the role of microalbuminuria in hypertensive disorders of pregnancy. 
 
1.15.2 DEFINITION OF MICROALBUMINURIA 
Microalbuminuria is defined as a urinary excretion rate of albumin between 20µg and 
200µg/min or between 30 mg/day and 300mg/day. Traditionally this has been 
measured using a 24 hour urine collection. The definition has been expanded to 
include spot urinary microalbumin to creatinine ratio (UAC) of 30 to 300mg/g. 
When using the UAC, various factors affecting albumin and creatinine excretion need 
to be taken into account. Factors affecting albumin excretion include blood pressure, 
time of day, fasting, salt intake and volume status (Khosla et al., 2006).   
 
During the 1990s, the most sensitive strips for detection of albuminuria had thresholds 
for detection of 20 mg/l. Thus a lower limit of 30 mg/day was chosen for the 
definition of microalbuminuria as the average daily urine output of 1.5 l was 
multiplied by 20mg/ l. The upper limit of 300 mg / day was chosen as the sensitivity 
of the older dipsticks for albumin was 100 to 300 mg/l (Heerspink et al., 2006). 
Recent studies have demonstrated that subjects with even slight increases in urinary 
albumin excretion in the normal range have an increase risk for development of 
cardiovascular morbidity and mortality (Gerstein et al., 2001) .This suggests that the 
limits chosen for microalbuminuria  are arbitrary and the best cut offs still need to be 
identified (Heerspink et al., 2006).   
 
1.15.3 PATHOPHYSIOLOGY OF MICROALBUMINURIA 
Microalbuminuria appears to be more a marker of vascular disease than a pathogenic 
factor. Factors known to influence the development of MA include an increased body 







lipoprotein levels, insulin resistance, smoking, salt sensitivity, increasing age and a 
DD ACE- genotype (Khosla et al., 2006; Verdecchia et al., 2004) 
Patients with MA have an elevated transcapillary escape rate of albumin, and usually 
the presence of one or more of the above risk factors. The mechanism of vascular 
injury differs among diabetic and hypertensive populations. In hypertensive patients 
with MA, increases in microvascular pressure results in endothelial damage, leading 
to generalized vascular leakiness. Excess protein is deposited in the extracellular 
matrix, resulting in the capillary basement membrane becoming sclerosed.This 
response is mediated through various stimuli such as, complement activation, 
macrophages, neutrophils, and endothelial stimulation from other inflammatory 
insults (Khosla et al., 2006; Verdecchia et al., 2004). 
 
 
In diabetic patients, the glycated state of albumin transforms it into an antigenic like 
molecule that is associated with generation of free oxygen radicals that causes direct 
injury to the glomerular membrane. This impairs glomerular filtration of proteins 
resulting in increased albumin excretion (Stehouwer et al., 1997; Khosla et al., 2006). 
The link between diabetic and non-diabetic MA may be impaired insulin resistance, 
leading to an increased amount of glycated albumin. 
 
1.15.4 MICROALBUMINURIA IN PREGNANCY 
Recently there has been interest in the measurement of microalbumin in the urine of 
pregnant women. Microalbuminuria is defined as urinary excretion of albumin that is 
persistently above normal, although below the sensitivity of conventional semi-
quantitative test strips (Maybury and Waugh, 2004).  
Proteinuria in pregnancy is due to selective glomerular filtration and non-selective 
(proximal tubule) reabsorption. In non-pregnant women there is an albumin filtration 







gradually increases with levels of 5mg/100ml in the first and second trimesters and 
10mg/100ml in the third trimester. Levels in the third trimester may reach 300mg/ml 
in normal pregnancy (Davison, 1985). The majority of additional albumin excretion in 
pregnancy is from nocturnal excretion (Douma et al., 1995). Gestation specific 
reference ranges for urinary microalbuminuria, creatinine concentration and 
microalbumin to creatinine ratio have been described for uncomplicated pregnancies 






1.15.5 MICROALBUMINURIA AND HYPERTENSIVE DISORDERS OF 
PREGNANCY 
It has been suggested that a phase of micoalbuminuria may precede overt proteinuria 
in pre-eclampsia (Bar et al., 1996). There has been mixed results in the literature on 
the usefulness of MA as an early predictor of pre-eclampsia.  
Lopez-Espinoza et al., (1986) found no evidence that gross proteinuria detected in 
patients with pre-eclampsia was preceded by a gradual increase in microalbuminuria, 
and Konstantin-Hansen et al., (1992)  concluded that MA could not be used  to predict 
pre-eclampsia in low risk pregnant women.  
Nakamura et al., (1992) in a study of 199 normotensive pregnant women at 20 and 30 
weeks of gestation, found the fasting urinary albumin to creatinine ratio to be 
significantly higher in women destined to develop pregnancy induced hypertension. 
Using a cut off value of more than 16mg/g as a positive test result, the negative 
predictive value was 94% for 20 weeks and 96% for 30 weeks gestation and thus they 








 Das et al., (1996) concluded that microalbuminuria was a significant risk factor for 
prediction of pre-eclampsia. Using  20 µg/ml of urinary albumin as a positive test, 
they found a sensitivity of 64, 42% and specificity of 91, 84%. 
Microalbuminuria dipsticks have also been used to detect clinically significant 
proteinuria (Higby et al., 1995; Waugh et al., 2005a). Higby et al., (1995) compared 
two screening tests for MA, namely the Micro-bumintest and Multistix 10SG with a 
24 hour quantitative urinary protein measurement. They found the Micro-bumintest to 
have good sensitivity (87%), specificity (99%), PPV (81%) and NPV (99%) compared 
to the Multistix 10SG which had a lower sensitivity (36%), specificity (97%), PPV 
(68%) and NPV (88%).  
 Besides being used as a predictor of pre-eclampsia it has also been suggested that 
MA may correlate better with other clinical measurements of disease severity as it  
 
may more accurately reflect the glomerular dysfunction associated with the 
glomerular endotheliosis of pre-eclampsia (Waugh et al., 2005a). 
 
 1.15.6 POINT OF CARE INSTRUMENTS 
 Microalbuminuria dipsticks compared to the traditional visual urinary dipsticks have 
also been shown to be a better screening test for clinically significant proteinuria 
(Higby et al., 1995; Waugh et al., 2005a). Various semi-quantitative dipstick tests 
have been used for detection of MA. In order to allow routine testing of the antenatal 
population for microalbuminuria, quantitative and semi-quantitative point of care 
urinanalysers have been developed.  
The DCA 2000 (Bayer Corp., Elkhart, IN) is a point of care instrument that provides a 
quantitative result of the UAC. Waugh et al., (2003a) found that the DCA 2000 is 
accurate for the measurement of albumin to creatinine ratios in the uncomplicated 
population. In the hypertensive pregnant population they found the DCA 2000 
remained accurate though when the albumin concentration was greater than 40mg/l 







sensitivity of 94% [95% CI (0.85-0, 98)] and specificity of 98% [95%CI (0.85-0.98)] 
to detect significant proteinuria (Waugh et al., 2005). 
 The Clinitek Microalbumin Reagent Strip (Bayer Corporation, Elkhart, IN) is a semi- 
quantitative dipstick test for MA that is read using the Clintek 50 portable urine 
chemistry analyzer. Waugh et al., (2005a) found that the Clinitek 50 system had a 
sensitivity of 58% [95% CI (0.47-0.70)] and specificity of 83% [95% CI (0.74-0.90)] 
for detecting significant proteinuria. The same study found the semi-quantitative 
visual Multistix 8SG used to detect proteinuria to have a lower sensitivity of 51% 




This type of automated point of care urine analyzers are able to provide rapid results, 
avoiding inter observer error and provide automated documentation of results. Based 
on the potential benefits of such instruments, we decided to test the clinical utility of 

























CHAPTER 2  
2.1 AIMS 
The use of semi-quantitative UAC dipstick analysis using point of care urinanalysers 
may offer significant advantages. These include decreasing the need for timed 24 hour 
urine collections, a reduced need for hospital admission and rapid availability of 
results with improved accuracy over other forms of dipstick urinalysis for proteinuria. 
We therefore decided to embark on study using the Clinitek® Microalbumin reagent 
strip (Bayer Healthcare LLC, USA) that is analysed on the Clinitek® urinalyser 
(Bayer Healthcare LLC, USA) with the following aims: 
 
 
  Determine the accuracy of spot UAC dipsticks and conventional 
visual dipsticks compared to laboratory UAC quantification to 
detect significant proteinuria in a normotensive and hypertensive 
population attending antenatal clinic. 
 
 Determine the accuracy of spot UAC dipsticks and conventional 
visual dipsticks compared to a 24 hour urine protein collection 








 Determine the role of proteinuria as determined by the 24 hour 
urinary protein and the UAC dipstick read on the Clinitek 50 










2.2 ETHICS AND STUDY LOCATION 
This was a prospective study conducted at hospitals serving the Durban Metropolitan 
region in South Africa, viz. King Edward VIII, R.K. Khan and Inkosi Albert Luthuli 
Central Hospitals. Institutional ethical approval was obtained (no.E042/05) and all 
participants gave consent. Recruitment began in January 2006 and ended in 

















































As previously mentioned, the use of point of care analysers to determine the UAC 
ratio in pregnancy, may offer significant advantages over conventional visual 
dipsticks in the assessment of significant proteinuria in pregnancy. We therefore 
embarked on a pilot study to validate the Clinitek 50 system by determining the 
accuracy of spot UAC   dipsticks and conventional visual dipsticks compared to 
laboratory UAC quantification to detect significant proteinuria in normotensive and 
hypertensive antenatal attendees. 
 
3.2 METHOD 
In order to validate the UAC dipstick we required participants with and without 
significant proteinuria. We thus chose one population group with a low prevalence of 
proteinuria (normotensives) and the other with a high prevalence (hypertensives). 
A series of 15 normotensive pregnant women and 11 women with new onset 
hypertension in pregnancy after 20 weeks of gestation were recruited at the antenatal 
clinic. Exclusion criteria included women with chronic renal disease, eclampsia and 







Each woman had a spot midstream urine (morning specimen) collected. A small 
amount of this specimen  was tested  for proteinuria using a semi-quantitative visual 
dipsticks (Makromed , Makro Medical, RSA) by trained midwifes at the antenatal 
clinic; another  small amount of the urine specimen was then analysed using the semi-
quantitative microalbumin:creatinine ratio dipsticks (Clinitek® Microalbumin, Bayer 
Healthcare LLC, USA) read on the Clinitek® 50 urine chemistry analyser. This test 
was carried out by two doctors who were specifically trained to use the instrument as 
a side room investigation. 
  
The results from the printout of the test and the semi-quantitative tests were recorded 
in a structured data sheet (Appendix 1). The remainder of the sample was then sent to 
the laboratory for quantitative measurement of the UAC. The midwives and the 
laboratory personnel were blinded to the results.  
The results of the semi-quantitative measurement of visual dipsticks (Makromed ) 
for proteinuria done routinely at the antenatal clinic and the UAC dipsticks were 
compared to the quantitative measurement of the UAC in the laboratory. A result of 
1 + on visual dipsticks was considered positive for proteinuria. A spot urinary 
microalbumin to creatinine ratio of > 300mg/g (33.9 mg/mmol) was considered as 
positive for significant proteinuria. Figure 5 illustrates a flow diagram of the 
methodology. 
 
3.3 TEST METHODS 
Semi-quantitative visual dipsticks (Makromed , Makro Medical, RSA) were used to 
test for proteinuria. This visual dipstick is sensitive for albumin (15-20 mg/dl 
albumin) with its active agent being tetrabromophenol blue. 
The dipstick test used to detect MA was the Clinitek® Microalbumin reagent strip 
(Bayer HealthCare LLC, USA). This test is based on albumin binding to 
sulphonephthalein dye and creatinine forming a copper creatinine complex that 







tetramethylbenzidine. Both these reactions produce colours that are read 
reflectometrically in the Clinitek 50 portable urine chemistry analyser. Albumin 
concentrations are reported as 10, 30, 80 and 150 mg/l, creatinine concentrations as 




The Multigent Microalbumin assay was used for the quantitative measurement of 
albumin on the spot urines on the Architect c6000  System. This assay is an 
immuno-turbidimetric assay that uses polyclonal antibodies against human albumin. 
The coefficient of variation (CV) of this assay was ≤ 5%. Creatinine was measured 
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3.4 STATISTICAL ANALYSIS 
 
With the use of the laboratory UAC as the standard, sensitivity, specificity, and 
positive and negative predictive values for the visual urinary dipstick and the UAC 
dipstick read on the Clinitek® 50 system was determined using the SPSS package 
(version 2006) for analysis. 
 
3.5 RESULTS  
 
A total of 26 pregnant patients were recruited of whom 15 were normotensive and 11 
were patients with hypertension. Table 3 shows the characteristics of the study 
population.  
 
 Table 4 shows the comparison of the UAC dipsticks and conventional visual 
dipsticks to the laboratory UAC quantification. The visual dipstick had a sensitivity of 
25% ( 95% CI [0.04-0.64] ) and specificity  of 89% ( 95% CI [0.64-0.98] ).The UAC 
dipsticks had  a sensitivity of  88% ( 95% CI [0.47-0.99] ) , specificity of  89%            
( 95% CI [0.64-0.98] ), negative predictive value of  94 % ( 95% CI [0.69-1.00]) and 
positive predictive value of 78% ( 95% CI  [0.40 -0.96]). 
 
The hypertensive and normotensive pregnant women were sub analysed and a 
comparison of UAC dipsticks to laboratory UAC quantification made in both groups 
(Table 5). In the normotensive group the sensitivity and specificity of the UAC 
dipstick was 67% (95% CI [ 0.13-0.98 ] ) and 92 % ( 95% CI [0.60-1.00 ] )  and in the 
hypertensive group it was 100% ( 95% CI [ 0.46-0.98 ] ) and 83% ( 95% CI [0.36-














Table 3.  Clinical characteristics of participants  
 
Number of participants 26 
Number of normotensives 15 
Number of hypertensives 11 
Age (mean) 27 years 
Parity   
         P0  8 
         P1-4 16 




Table 4: Comparison of UAC dipsticks and conventional visual dipsticks to 
laboratory UAC quantification  
 






















**A UAC of < 300mg/g (nil and trace on urine dipsticks) was considered to be a 
negative result. A UAC  300 mg/g (1+ to 4+ on urine dipsticks) was considered to be 
a positive result. 







 PPV   = Positive Predictive Value 





Table 5 Comparison of UAC dipsticks to laboratory UAC quantification in 
normotensive and hypertensive pregnant women  
 
 n SENSITIVITY SPECIFICITY PPV NPV 

















** A UAC of <300mg/g (nil and trace on urine dipsticks) was considered to be a 
negative result. A UAC 300 mg/g (1+ to 4+ on urine dipsticks) was considered to be 
a positive result. 
 NPV = Negative Predictive Value 
PPV   = Positive Predictive Value 
 [ ]      = 95 % Confidence Interval 























3.6 DISCUSSION:  
 
Visual dipsticks are used routinely to screen for proteinuria in pregnancy. Detection of 
1+ or more of proteinuria on visual dipsticks in the hypertensive pregnant patient is 
followed by the measurement of total urinary protein over a 24 hour period which is 
used as the gold standard in the diagnosis of pre-eclampsia.  
 
Although the ISSHP has proposed the use of spot urinary protein to creatinine ratio as 
an alternative to the 24 hour urine collection it does not appear to be widely used in 
practice (Cōté et al., 2008) .The majority of our patients have a 24 hour urine 
collection as inpatients in order to overcome difficulties with collection and 
transportation problems. This contributes to an increase in the number of admissions 
and financial costs to the hospital services. At the same time pre-eclampsia is a major 
cause of maternal mortality and both the early and correct diagnosis together with the 
institution of appropriate management is critical in preventing both maternal and 
perinatal mortality. We have thus looked at newer methods to screen for proteinuria. 
 
 The measurement of albumin excretion has been suggested as an alternative to total 
protein measurement as it may provide a more reliable methodology with improved 
sensitivity (Newman et al., 1995). The results of this study show the Clinitek system 
to have improved sensitivity and predictive values compared to the visual dipstick.  
 
In pregnancy, the Clinitek 50 system has been evaluated in hypertensive women. 
Waugh et al., (2005a) in a study comparing various methods for detecting significant 
proteinuria have shown a sensitivity of 58% [95% CI (0.47, 0.70)] and a specificity of 
83% [95% CI (0.74, 0.90)] compared to the 24 hour urinary protein. In our study, we 
chose to initially compare the semi quantitative UAC dipstick to the quantitative 
laboratory UAC measurement, in order to validate the UAC dipstick method prior to 











The Clinitek system has mainly been evaluated in the non pregnant diabetic 
population in screening for microalbuminuria. Le Floch et al., (2001) screened 302 
diabetic outpatients for microalbuminuria using the Clinitek system and compared it  
to the reference method of the biological laboratory. Using a positive result as UAC 
ratio of   30mg/g they found a sensitivity of 79% , specificity 81%, PPV 46% , NPV  
95% and likelihood ratio of 4.2.They concluded that due to the excellent NPV, the 
Clinitek system was a good screening test for microalbuminuria and that positive 
results should be confirmed using a reference assay.  
 
Parsons et al., (1999) evaluated the performance of the Clinitek system and compared 
it to a lateral flow device for the semi-quantitation of albumin (Micral 11 Roche 
Diagnostics, Lewes, UK) and also a laboratory based procedure. The imprecision of 
the Clinitek device was assessed by observing the discrepancy between duplicates in 
144 urine samples from patients with diabetes and or renal disease. Discrepancies in 
the albumin estimation were 6.9% and creatinine estimation was 12.5%. Using a UAC 
ratio with a cut off of < 30mg/g they found the Clinitek system to have a sensitivity of 
76.3%, specificity of 89.1% and a PPV of 89%. 
 
 In a study of 127 urine samples from paediatric patients with various disorders, Osta 
et al., (2003) compared the Clinitek 50 system and the DCA 2000 analyser against 
usual reference laboratory methods. Using an albumin cut off of 30 mg/l , they found 
the Clinitek 50 system had a sensitivity of 91.7 % , specificity 86%, positive 
predictive value 55% and  negative predictive value of 98%. They concluded the 
Clinitek system is a semi-quantitative method that is easy to use, low in cost and 
useful for screening. Table 6 shows a summary of the findings of the above studies. 
 
This is a pilot study and is limited by the small number of participants. It is however 
to the best of our knowledge, the first study to compare the semi- quantitative UAC 







measurement in a normotensive and hypertensive pregnant population. Although a 
sub analysis of the two groups was done (Table 5), the study was not powered to  
 
 
detect differences between the normotensive and hypertensive participants. 
 
 The results of the visual dipsticks were in keeping with those noted in a previous 
study ( Gangaram et al.,2005).The visual urinary dipsticks (Makromed ) were not 
accurate with low sensitivity and negative predictive values (Table 4). There are 
several reasons for the inaccuracy of visual dipsticks. These include inter-observer 
error and that dipstick urinalysis on random antenatal urine specimens yields a 
measure of protein concentration at a given time. The use of the UAC obviates the 
latter as the day urinary protein and creatinine excretion rates are fairly constant 
provided GFR is constant thus cancelling the time factor. Use of a point of care 





























Table 6: Summary of previous studies reporting performance of the Clinitek 50 




NPV = Negative Predictive Value 
PPV   = Positive Predictive Value 















Reference n Cut off Sensitivity Specificity PPV NPV 
Le Floch et 
al.,(2001) 
302 30mg/g 79% 81% 46% 95% 
Parsons et 
al.,(1991) 




127 30 mg/l 
albumin 









3.7 CONCLUSION  
 
The UAC dipstick read on the Clinitek 50 system provides a semi-quantitative result 
of the UAC that has a good sensitivity and specificity. Due to its good NPV, a result 
of < 300mg/g would rule out significant proteinuria and avoid unnecessary 
investigations in the pregnant population. The Clinitek 50 system is a point of care 
instrument that is user friendly, provides rapid results in the form of a print out, and 
avoids interobserver error. It thus provides a better alternative to visual dipsticks for 
screening for proteinuria. Further research is required to see how it compares to the 




























CHAPTER 4 - COMPARISON TO 24 HR URINARY PROTEIN  
 
4.1 INTRODUCTION 
The 24 hour urinary protein collection has been used as the gold standard for 
quantification of proteinuria in HDP. However, the procedure is time consuming, 
cumbersome and prone to collection errors. Visual dipsticks are used routinely to 
screen for proteinuria but have been shown to have poor sensitivity and specificity 
(Gangaram et al., 2005). In Chapter 3, we have shown that the UAC dipstick read on 
the Clinitek 50 system provides a semi-quantitative result of the UAC that has good 
sensitivity and specificity when compared to the laboratory UAC. Use of this point of 
care system may therefore reduce the need to perform 24 hour urine collections. We 
therefore embarked on a study to determine the accuracy of spot UAC dipsticks and 
conventional visual dipsticks compared to a 24 hour urinary protein (gold standard) to 
detect significant proteinuria in HDP. 
4.2 METHOD 
Women presenting to the antenatal clinic with hypertension during pregnancy after 20 
weeks of gestation were recruited. Hypertension was defined as a blood pressure of at 
least 140mmHg (systolic) or at least 90 mmHg (diastolic) on two occasions 4- 6 hours 
apart. Women with eclampsia, diabetes, chronic renal disease and urinary tract 
infection were excluded from the study. 
 In our setting hypertensives in pregnancy are routinely admitted for investigations 
and planning of clinical management. Routine investigations include assessment of 
the haematological and renal systems. On admission each participant has a spot urine 
sample that is tested by trained midwives for proteinuria using a semi-quantitative 









 In addition, a spot midstream urine sample was collected and analysed using the 
semi-quantitative UAC dipsticks (Clinitek® Microalbumin, Bayer Healthcare LLC, 
USA) read on the Clinitek® 50 urine chemistry analyser. This test was carried out by 
two doctors who were specifically trained to use the instrument as a side room 
investigation. 
 A 24 hour urine collection was then commenced and a quantitative measurement of 
protein in the urine was estimated in the laboratory (figure 6). Both the clinician 
managing the patient and laboratory technician measuring the 24 hour urine protein 
were blinded to the results of the UAC dipsticks, thus not interfering with standard 
patient management. Results were recorded in a structured data sheet (Appendix 2). 
 
4.3 TEST METHODS 
The test methods utilized was the semi - quantitative visual dipsticks (Makromed , 
Makro Medical, RSA) and the Clinitek 50 system as described in chapter 3.The 
quantitative 24 hour total urinary protein was measured by the Biuret method on a  
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         MICROALBUMIN /CREATININE 
          RATIO USING UAC  
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With the use of the quantitative 24 hour urinary protein  as the gold standard, 
sensitivity, specificity, and positive and negative predictive values for the visual 
urinary dipstick and the UAC dipstick read on the Clinitek® 50 system was 
determined using the SPSS package for statistical analysis. A negative result was 
considered to be a UAC of < 300mg/g (nil and trace on urine dipsticks). A positive 
result was a UAC  300 mg/g (1+ to 4+ on urine dipsticks).Urinary protein  0.3 g/24 




4.5 RESULTS  
 
A total of 163 participants were recruited. Their mean age was 28 years and there 
were 20 primigravida and 143 multiparous patients. Table 7 shows the characteristics 
of the study population.  
Table 8 shows the comparison of the semi-quantitative UAC dipsticks and 
conventional visual dipsticks to the quantitative 24 hr urinary protein measurement. 
The visual dipstick had a sensitivity of 51 % (95% CI [0.41-0.61]) and specificity of 
91% (95% CI [0.81-0.96]) .The PPV and NPV was 89 % (95% CI [0.77-0.95]) and 
58% (95% CI [0.48-0.67]) respectively.  
The UAC dipsticks had a sensitivity of 63% (95% CI [0.52-0.72]) and specificity of 
81 % (95% CI [0.70-0.89]). The PPV was 82% (95% CI [0.71-0.90]) and NPV was 

















Number of participants 163 
Age (mean)  28 years 
Parity   
         P0  20 
         P1-4 141 





Table 8: Comparison of semi- quantitative UAC dipsticks and visual dipsticks to the 
quantitative 24 hr total urinary protein measurement in the study population  
 
 Sensitivity  Specificity  PPV NPV 

















**A UAC of <300mg/g (nil and trace on urine dipsticks) was considered to be a 
negative result. A UAC 300 mg/g (1+ to 4+ on urine dipsticks) was considered to be 
a positive result. Urinary protein  0.3 g/24 hrs was considered significant proteinuria. 
NPV = Negative Predictive Value 
PPV   = Positive Predictive Value 














The results show that both the visual dipstick and the UAC dipstick, read on the 
Clinitek 50 system are not accurate when compared to the total 24 hour urinary 
protein. Whilst the Clinitek 50 system had a better sensitivity than the visual dipstick, 
overall they both showed low sensitivity and poor negative predictive values. 
 
In a previous study (Gangaram et al., 2005) we have shown the visual dipstick done 
on a spot urinary sample to be inaccurate. The two main reasons postulated for this 
include inter observer error and the fact that various factors may influence urinary 
protein concentration at a given point in time. By using an automated device like the 
Clinitek 50 system, it was thought that inter observer error would be omitted. The 
slightly improved sensitivity of the Clinitek 50 system as compared to the visual 
dipstick probably reflects this to a certain extent, however it suggests that it probably 
isn‟t a major contributor to inaccuracy of the visual dipstick in an environment where 
there is trained staff routinely conducting the test. 
 
 A 24 hour urinary collection is done to account for the variation in protein excretion 
that occurs during the day. By doing a protein to creatinine ratio on the spot urinary 
sample, the time factor is cancelled and thus the ratio reflects the cumulative excretion 
during the day. We measured the urinary albumin as opposed to the total urinary 
protein and this may explain the differences in results. As albumin only accounts for 
about 10% of total protein excretion in pregnancy (Higby et al.,1995)  and the non 
selective proteinuria of pre-eclampsia contains a range of molecular weight proteins 
(Waugh et al.,2005a) , this may explain why UAC ratio did not closely predict total 
protein excretion. Waugh et al., (2005a) have suggested that microalbuminuria may 
correlate better with other clinical parameters of disease severity as it may more 
accurately reflect the glomerular pathology associated with the glomerular 




Another factor that may have influenced the results is the lack of clear guidelines in 
the literature of what should be the gold standard for measurement of total urinary 







measurement may vary according to the assay used (Waugh et al., 2001). This may 
have been a further confounding variable in the study. 
 
In a study of 171 hypertensive pregnant women Waugh et al., (2005a) compared the 
visual dipstick (Multistix 8SG), automated Multistix 8SG and UAC dipstick read on 
the Clinitek 50 system to the 24 hour urinary protein excretion (300mg/24hrs). They  
found that the use of an automated visual dipstick ( Multistix 8SG) improved 
sensitivity from 51% [95% CI (0.39-0.62)] to 82% [95% CI (0.71-0.90)].They  also 
found the automated UAC dipstick, using a threshold of 3.4 mg albumin / mmol 
creatinine  to have a sensitivity of 58% [95% CI (0. 45-0.70)] , specificity of  83%      
[95% CI (0. 74-0.90]) , likelihood ratio for a positive result (LR+) 3.43 [95% CI (2.12 
-5.57)] and likelihood ratio for a negative result (LR-) of 0,50 [95% CI (0.38-0.66)]. 
 
 In the same study the DCA 2000, which is a point of care device that gives a 
quantitative measurement of microalbumin performed significantly better for the 
detection of „significant proteinuria‟ in hypertensive pregnancies. Using a cut off 
value of 2mg albumin/mmol creatinine they found a sensitivity of 94% [95% CI 
(0.85-0.98)], specificity 94% [95% CI (0.85-0.98), LR+ of 14.6 [95% CI (6.74-31.8)] 
and LR- of 0.069 [95% CI (0.030-0.16)]. They hypothesized that the improvement 
seen with the DCA 2000 was partly due to the use of appropriate pregnancy specific 
thresholds which are not reflected by conventional dipsticks. 
 
Bar et al., (1996) suggested that a phase of microalbuminuria may precede pre-
eclampsia. Our study was limited by the fact that we evaluated the UAC to detect 
significant proteinuria only. It is possible that some of the clinical causes of our false 
positives may have been attributed to participants who would have gone on to develop 
pre-eclampsia at a later stage. In their study of the DCA 2000, Waugh et al., (2005a) 




Technical considerations in terms of assay technique of the Clinitek 50 system may 
have also contributed to some of the false positives and false negatives. Parsons et al., 







albumin estimation was 6.9% and creatinine estimation was 12.5%. They found a 
decrease in sensitivity, specificity and positive predictive value for the UAC 
compared with the albumin value alone for the Clinitek system and attributed this to 




4.7 CONCLUSION   
 
Both the visual dipstick (Makromed ) and the UAC dipstick read on the Clinitek 50 
system are not accurate when compared to the total 24 hour urinary protein. Reasons 
for inaccuracy of the visual dipstick include inter-observer error and factors that affect 
urine concentration. Differences between the UAC and 24 hour urinary protein may 
be due to the variation in the albumin fraction of the total urinary  protein of pre-
eclampsia, technical problems with imprecision of the  assay technique and clinical 
causes of false positives and negatives. The improved sensitivity of the automated 
UAC dipstick over the visual dipstick suggests it may be a suitable substitute for the 
visual dipstick in clinical practice. It is a point of care instrument that is easy to 
operate, provides rapid results in a print out form and avoids inter-observer error. 
Whether the UAC correlates better to other clinical measurements of disease severity 























In chapter 4, the study results showed that the UAC dipstick read on the Clinitek 50 
system is not accurate when compared to total 24 hour urinary protein estimation. It 
has been suggested that MA may correlate better with other clinical measurements of 
disease severity as it may more accurately reflect  glomerular dysfunction associated 
with the glomerular endotheliosis of pre-eclampsia (Waugh et al., 2005a). We 
therefore determined the role of proteinuria as determined by the 24 hour urinary 
protein and the UAC dipstick read on the Clinitek 50 system on pregnancy outcomes 




Women recruited to the study described in chapter 4 were followed up. The outcomes 
of pregnancy in 2 sub-categories viz. those with and without proteinuria were 
compared. Significant proteinuria (≥ 0.3g/24 hours) was measured by the gold 
standard 24 hour urinary protein and the UAC dipstick read on the Clinitek 50 system. 
The pregnancy outcomes were compared utilizing the following variables: 
 
Maternal outcomes: 
1. Gestational age at delivery. 
2. Caesarean section – Primary elective / emergency 
3. Induction of labour 




1. Stillbirths / early neonatal deaths 
2. Birth weight 







4. Perinatal mortality  
 
 
5.3 STATISTICAL ANALYSIS 
 
Outcome of pregnancy was compared between those with pre-eclampsia (proteinuria 
≥0.3g/24 hours as measured by the quantitative 24 hour urine collection) and those 
with gestational hypertension. The SPSS package was used for statistical analysis. 
Analyses testing of the frequency of adverse events within the groups were done using 
the Chi-square test. Birthweights were compared using Student-t test, whilst apgar 
scores and biochemical indices were compared using the Mann -Whitney U test. 
 
 A secondary analysis of outcomes of pregnancy was performed by sub-categorizing 
the participants according to the diagnostic accuracy of the UAC dipsticks. A UAC of 
< 300mg/g was considered to be a negative result and UAC  300 mg/g a positive 
result. Analyses testing of  the frequency of adverse events within groups was done 
using the Chi-square test with Bonferroni correction. ANOVA was used to calculate 










5.4 RESULTS  
 
Outcome of pregnancy in hypertensives as classified according to the 24 hr 
urinary protein 
 The outcomes of pregnancy in 163 hypertensives were compared between those with 
pre-eclampsia (proteinuria ≥ 0.3g/24 hours as measured by the quantitative 24 hour 







available for 155 patients. There was incomplete data available for 8 patients. Reasons 
for this included patients delivering at other healthcare facilities or delivery prior to  
coming to hospital due to lack of accessibility to transport. There were 69 gestational 
hypertensives (GH) and 94 patients with pre-eclampsia (PE).  
 
Table 9 shows the baseline characteristics at entry in the two groups. Table 10 shows  
the laboratory parameters of the two groups at entry. Baseline platelet count was 
significantly lower in the PE group (222.5 vs. 245 x 10
9
/ l, p =0.045). Urea, creatinine 
and urates were significantly higher in the PE group. These results are in keeping with 
the endothelial and renal dysfunction associated with pre-eclampsia. 
 
Table 11 shows the maternal outcomes in the groups. Mean gestational age of 
delivery was significantly lower in the PE group, 36 weeks compared to 38 weeks in 
the GH (p =0.003).There was a trend towards more caesarean sections in the PE group 
(69.1% vs. 49.2%) with the majority being emergency caesarean sections (69.1% vs. 
50%). 
 
Of the vaginal deliveries there were significantly more inductions in the PE group       
(62.9% vs. 21.2%). There was no maternal mortality in either group and there was a 
trend towards increased maternal morbidity in the PE group (8.8% vs. 4.6%). We 







Table 12 shows the perinatal outcomes in the groups. The mean birthweight was 
significantly lower in the PE group (2351g vs. 2854g, p < 0.001). This may have been 
as a result of intrauterine growth impairment or preterm delivery. There was no 
significant difference in the apgar scores in the two groups.  There was a trend 
towards an increase in perinatal mortality in the PE group (10% vs. 3.1%, p =0.053). 
 








We assessed whether the UAC ratio correlates better to clinical measurements of 
disease severity and clinical outcomes. While false positives for PE may lead to over 
investigation, false negatives may lead to less close surveillance and result in serious 
maternal and perinatal consequences. Outcomes of pregnancy were re-analyzed by 
sub-categorizing the participants according to the diagnostic accuracy of the UAC 
ratio dipsticks.  
 
 Table 13 shows the baseline laboratory parameters. There were no significant  
differences between the true negatives and false negatives in the GH group except for 
the higher median creatinine value in the false negatives.  
There were also no significant differences in terms of gestational age of delivery, 
maternal morbidity (Table 14) and the perinatal outcomes (Table 15) between the true  
negatives and false negatives in the GH group. The only difference noted was in the 
mode of delivery with a trend to a higher caesarian section rate in the false negatives 











Table 9: Baseline characteristics at entry in the study groups  
 
At entry GH PE 











     P0 6 14 
     P1-4 62 79 
     P>4 1 1 
 
GH    = Gestational Hypertension 
PE     = Pre- eclampsia  




Table 10: Baseline Laboratory parameters in the study groups  
 
(median) GH PE p-value 
Platelets (x10
9 
/l) 245 222.5 0.04 
Urea   (mmol/l)        2.1 2.5 0.001 
Creatinine (µmol/l) 53 63.5 0.001 
Urates (mmol/l) 0.25 0.3 0.004 
  
GH = Gestational Hypertension 






Table 11: Maternal outcomes in the study groups  
 
 GH (n=65) PE(n=90) p- value 
Mean gestational age at 
delivery(weeks) 
38 36 0.003 
    
Mode of delivery    







        Emergency c/s 16 (50%) 38 (69.1%)  
        Elective c/s 16 (50%) 17 (30.9%)  
    
Vaginal delivery 33 (50.8%) 35 (38.9%) 0.001 
        Spontaneous 26 (78.8%) 13 (37.1%)  
        Induced 7 (21.2%) 22 (62.9%)  
    
Morbidity 3 (4.6%) 8 (8.8%) 0.19 
       Abruptio Placentae 2 1  
       Eclampsia 0 1  
        High care admission 1 6  
    
 
GH = Gestational Hypertension 
PE   = Pre- eclampsia  









Table 12: Perinatal outcomes in the study groups 
 
 GH(n=65) PE(n=90) p- value 
    
Mean Birthweight (grams) 2854 2351 0.001 
    
Apgars (median)    
   1 minute  8 8 0.074 







    
Perinatal Deaths 2 (3.1%) 9 (10%) 0.053 
           MSB    (n) 1 6  
            FSB    (n) 0 0  
            ENND (n) 1 3  
 
GH      = Gestational Hypertension 
 PE       = Pre- eclampsia  
 n          = Number of patients 
 MSB  = macerated stillbirth 
 FSB    = fresh stillbirth 












Table 13: Baseline Laboratory parameters in the study groups as classified by the 
UAC dipsticks 
 












/l) 212 238 239 248 0.016 
Urea (mmol/l)        2.6 2.2 2.2 2.1 0.001 
Creatinine (µmol/l)        100 125 108 126 0.001 








GH  = Gestational Hypertension 





















Table 14: Maternal outcomes in the study groups as classified by the UAC dipsticks 
 










 n 55 13 35 52  
      
Mean gestational age at 
delivery(weeks) 







      
Mode of delivery      
Caesarean section (c/s) 33 (60%) 7(53.8%) 22(62.9%) 25(48.1%) 0.180 
        Emergency c/s 23(69.7%) 5(71.4%) 15(68.2%) 11(44%)  
        Elective c/s 10(30.3%) 2(28.6%) 7(31.8%) 14(56%)  
      
Vaginal delivery 22(40%) 6(46.2%) 13(37.1%) 27(51.9%) 0.02 
        Spontaneous 6(27.3%) 5(83.3%) 7(53.8%) 21(77.8%)  
        Induced 16(72.2%) 1(16.7%) 6(46.2% 6(22.2%)  
      
Morbidity 6(10.9%) 0 2(5.7%) 3(5.8%) 0.025 
       Abruptio Placentae 0 0 1 2  
       Eclampsia 0 0 1 0  
        High care admission 6 0 0 1  
      
 
 GH = Gestational Hypertension 
 PE  = Pre- eclampsia  




Table 15: Perinatal outcomes in the study groups as classified by the UAC dipsticks 
 










      
Birthweight (grams) 2092 2884 2760 2847 0.001 
      
Apgars      
   1 minute ( mean) 8 8 8 8 0.197 







      
Perinatal Deaths 8 (14.5%) 1 (7.7%) 1 (2.9%) 1 (1.9%) 0.053 
           MSB    (n) 5 0 1 1  
            FSB    (n) 0 0 0 0  
            ENND (n) 3 1 0 0  
 
 GH      = Gestational Hypertension 
 PE       = Pre- eclampsia  
 MSB   = macerated stillbirth 
 FSB     = fresh stillbirth 
 ENND = early neonatal death 










5.5 DISCUSSION  
 
Our results show that in hypertensive pregnant women, significant proteinuria 
determined by the quantitative 24 hour urinary protein is associated with delivery at 
an earlier gestational age, increased induction of labour and lower birthweights 
compared to the non – proteinuric hypertension (gestational hypertension). There is 
also a trend towards an increased maternal morbidity and perinatal mortality. These 
findings are similar to those of previous studies which have demonstrated that 
proteinuria associated with hypertension in pregnancy is associated with greater 
adverse maternal and fetal outcomes (Chan et al., 2005; Brown et al., 1996; 








When the groups were classified into PE and GH using the UAC dipsticks, there were 
no differences in the clinical outcomes between the false negatives and true negatives 
except a trend towards a higher caesarean section rate in the false negatives. The 
results suggest that classification as GH based either on a quantitative 24 hour urinary 
protein collection or a negative UAC dipstick test is associated with a similar clinical 
outcome. Thus there appears to be a good correlation between the UAC and 
measurements of disease severity and clinical outcomes in hypertensive pregnant 
women. 
 
There are several possible explanations for this. The clinical syndrome of PE is 
thought to be due to maternal endothelial dysfunction .This is thought to result from 
placental hypoxia with oxidative stress or from the interaction between a normal 
placenta and conditions that make the mother susceptible to microvascular disease 
(Redman et al., 2005) .The net result of endothelial dysfunction is an increase in 
vascular permeability systemically and at glomerular level. Microalbuminuria occurs 






Furthermore, urinary albumin has been shown to be a sensitive marker to early 
changes in glomerular permeability (Newman et al., 1995) and thus the UAC may 
detect structural renal changes associated with pre-eclampsia earlier.  
 
 The findings of this study  is important in the clinical context as it demonstrates that 
the UAC dipstick is a good screening test to rule out significant proteinuria. The 
visual dipstick test which is widely used is a poor screening test (Gangaram et 
al.,2005) while the gold standard 24 hour urinary protein is far from perfect. It is a test 
which is cumbersome, time consuming, prone to collection error and leads to delay in 
diagnosis. Lack of a gold standard assay for measurement of protein may also 
contribute to its inaccuracy (Waugh et al., 2005b). Use of the UAC may lead to a 







in hospital admissions. A positive UAC dipstick test still mandates a 24 hour urinary 
protein collection to accurately quantify proteinuria and confirm the diagnosis.  
 
Although the ISSHP and the Australasian Society for the Study of Hypertension in 
pregnancy have proposed the use of the spot urinary protein to creatinine ratio as an 
alternative to the 24 hour urinary collection (Brown et al.,2001; Brown et al., 2000) , 
it doesn‟t appear to be widely used ( Cōté et al.,2008).A recent systematic review        
( Cōté et al.,2008) found the spot protein to creatinine ratio to be a reasonable „rule- 
out‟ test for detecting significant proteinuria in hypertensive pregnancy , however , 
the review  found information on the use of the UAC to be  limited. Our results 
suggest that the UAC dipstick read on the Clinitek 50 system would be a reasonable 
rule out test. In addition, it would be more amenable to widespread use as it is a point 
of care system that can be easily used by midwives and doctors and provides rapid 
results in the form of a printout. 
 
Limitations of the study include that participant numbers were not large enough to 
demonstrate the expected finding of a significant difference in perinatal mortality and 
maternal morbidity between the two groups. We also did not analyse perinatal 
morbidity in detail.  
 
Although we did not do a detailed cost analysis, approximate cost per test of the 
visual dipstick is R10, UAC dipstick R15 and 24 hour urinary protein R45 (admission 
costs not included). A reduction in the number of unnecessary 24 hour urinary protein 
tests done may justify the added cost of the UAC dipstick compared to that of the 
visual dipstick. 
 
While false positives in screening may lead to over diagnosis and an increase in 
surveillance and cost, it may be justified in a condition like PE where one is trying to 
prevent adverse maternal and fetal outcome. The UAC dipstick read on the Clinitek 
50 system is a new technique that has potential to improve accuracy of screening for 












Hypertensive pregnancy associated with significant proteinuria is associated with 
greater adverse maternal and fetal outcome. Outcome of pregnancy is similar when a 
classification of GH is made based either on the 24 hour urinary protein collection or 
the UAC dipstick read on the Clinitek 50 system. The UAC dipstick is a good 
screening test to rule out significant proteinuria. It has potential to improve accuracy 
of screening for proteinuria and enhancing safety by preventing incorrect diagnosis. 












CHAPTER 6  
 
 
6.  SUMMARY OF FINDINGS 
 
Antenatal screening for pre-eclampsia consists predominantly of detection of a raised 
blood pressure and proteinuria. Traditionally screening for proteinuria has consisted 
of performing a semi-quantitative visual dipstick test. If positive for significant 
proteinuria this is then followed by a quantitative 24 hour urinary protein.  
 
The visual dipstick has been shown to be inaccurate (Gangaram et al., 2005), while 
the 24 hour urinary protein collection is cumbersome and fraught with collection 
errors. New developments in proteinuria assessment have included the use of urinary 
albumin measurements. This study has investigated the role of the UAC dipstick read 








The initial investigation was to validate the UAC dipstick in both a normotensive and 
hypertensive pregnant population. It showed  that the UAC dipstick read on the 
Clinitek 50 system provides a semi-quantitative result of the UAC that has a good 
sensitivity 0.88 ( 95% CI [0.47-0.99] ) and specificity 0.89 ( 95% CI [0.64-0.98]). Due 
to its good NPV 0.94 (95% CI [0.69-1.00]), a result of < 300mg/g would rule out 
significant proteinuria and avoid unnecessary investigations in the pregnant 
population. It thus provides a better alternative to visual dipsticks for screening of 
proteinuria. 
 
A comparison was then made between the visual dipstick and the UAC dipstick read 
on Clinitek 50 system and the 24 hour urinary protein which is the current „gold 
standard‟. Both the visual dipstick and the UAC dipstick were found to be inaccurate. 
Reasons for inaccuracy of the visual dipstick include inter-observer errors and factors 
that affect urine concentration. Differences between the UAC and 24 hour total  
urinary protein may be due to the variation in the albumin fraction of the total urinary  
protein of pre-eclampsia, technical problems with imprecision of the  assay technique 
and clinical causes of false positives and negatives. 
 
 
We then set out to determine if the UAC correlates better to other clinical 
measurements of disease severity or clinical outcomes. The findings were that  
hypertensive pregnancies associated with significant proteinuria as determined by the 
24 hour urinary protein is associated with greater adverse maternal and fetal outcome.  
 
Pre-eclampsia was associated with delivery at an earlier gestational age, increased 
induction of labour and lower birthweights compared to GH. There was also a trend 
towards an increased maternal morbidity and perinatal mortality in the PE group. We 
found that the outcome of pregnancy is similar when a classification of GH is made 
based either on the 24 hour urinary protein or the UAC dipstick read on the Clinitek 
50 system. A possible reason for the good clinical correlation of the UAC may be 
related to the fact that microalbuminuria is a marker of endothelial dysfunction which 
is responsible for many of the clinical manifestations of pre-eclampsia. Furthermore 








 The UAC dipstick is a good screening test to rule out significant proteinuria. A 
positive result would still require quantification of proteinuria using the 24 hour 
urinary collection. It has potential to improve accuracy of screening for proteinuria 
and enhancing safety by preventing incorrect diagnosis. It is also more likely to be 
used widely in the clinical setting since it is a point of care system that is easy to use 
and provides rapid results in the form of a printout. Further research is required to 
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5. Gestational age (entry): 
 





7. Visual dipstick 















8. UAC dipstick 
    a. Microalbumin: 
    b. Creatinine 
    c. UAC:  
 
9. Laboratory Quantification 
       a. microalbumin 
       b. Creatinine 









                                               APPENDIX 2 
 
 


















7. Visual dipstick 
















    a. Microalbumin: 
    b. Creatinine 
    c. UAC:  
 
9. 24 hr urinary collection 
       a. Total protein 
       b. Creatinine clearance 































c. Elective C/S 






c. HELLP syndrome 











21. Apgar score (Birth): 
 
22. Apgar score (5min): 
 
23. Mortality 






24. Birth weight: 
